Last reviewed · How we verify
Infliximab (INF) + MTX, DB
Infliximab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling, while methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) that inhibits folate metabolism and immune cell proliferation.
Infliximab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling, while methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) that inhibits folate metabolism and immune cell proliferation. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Infliximab (INF) + MTX, DB |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | TNF-alpha inhibitor + DMARD combination |
| Target | TNF-alpha receptor; dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Infliximab is a chimeric monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. Methotrexate works through multiple mechanisms including inhibition of dihydrofolate reductase and suppression of T-cell activation. The combination targets inflammatory pathways synergistically to reduce disease activity in autoimmune conditions.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Headache
- Nausea
- Tuberculosis reactivation
- Hepatotoxicity
Key clinical trials
- Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) (PHASE3)
- Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infliximab (INF) + MTX, DB CI brief — competitive landscape report
- Infliximab (INF) + MTX, DB updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI